Relmada Therapeutics Inc
NASDAQ:RLMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Relmada Therapeutics Inc
Stock-Based Compensation
Relmada Therapeutics Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
Stock-Based Compensation
$15m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
31%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Stock-Based Compensation
$1.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Stock-Based Compensation
$553m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
9%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Stock-Based Compensation
$799m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Stock-Based Compensation
$820m
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Stock-Based Compensation
$626m
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
Relmada Therapeutics Inc
Glance View
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Coral Gables, Florida and currently employs 10 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).
See Also
What is Relmada Therapeutics Inc's Stock-Based Compensation?
Stock-Based Compensation
15m
USD
Based on the financial report for Dec 31, 2025, Relmada Therapeutics Inc's Stock-Based Compensation amounts to 15m USD.
What is Relmada Therapeutics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
31%
Over the last year, the Stock-Based Compensation growth was -50%. The average annual Stock-Based Compensation growth rates for Relmada Therapeutics Inc have been -30% over the past three years , -6% over the past five years , and 31% over the past ten years .
